Arthrocentesis
2061020611wRVU: 1.07 — Arthrocentesis, major joint WITH ultrasound guidance (replaces 20610 when US used)20605wRVU: 0.66 — Arthrocentesis, intermediate joint without US (wrist, elbow, TMJ)20606wRVU: 0.98 — Arthrocentesis, intermediate joint WITH ultrasound guidance20600wRVU: 0.64 — Arthrocentesis, small joint without US (finger, toe)76942wRVU: 0.65 — US guidance (only when billed separately from injection codes — see billing tip)
[Knee / shoulder / hip / ankle] effusion, [septic arthritis / gout / pseudogout / traumatic / inflammatory arthritis / unknown]
Same
Arthrocentesis, [right / left] [knee / shoulder / hip / ankle] [with / without] ultrasound guidance
[Attending name], MD
N/A
Local: 1% lidocaine infiltrated to skin and subcutaneous tissue. [Ultrasound-guided approach used.]
Patient presents with [painful / swollen / warm] [right / left] [knee] with [X] mL clinical effusion. [Fever / leukocytosis / elevated CRP / trauma] present. Concern for [septic arthritis / crystal arthropathy / inflammatory flare]. Arthrocentesis indicated for diagnosis and relief. Risks including infection, bleeding, joint injury, and vasovagal response discussed. Consent obtained.
[Clear / cloudy / yellow / bloody / purulent] synovial fluid aspirated. [X] mL removed. [Sent for cell count, differential, crystal analysis, gram stain, and culture / Gram stain and culture sent given concern for infection.] [Corticosteroid / hyaluronic acid injected after aspiration.]
The patient was positioned [supine / seated] with the [right knee / shoulder] in [mild flexion / abduction / neutral]. The [knee / shoulder] was identified by [palpation / ultrasound landmarks]. The skin was prepped with [betadine / chlorhexidine]. [1% lidocaine was infiltrated to the skin and subcutaneous tissue.]
A [18-gauge (knee with viscous/purulent fluid) / 20-gauge (knee standard, shoulder) / 22-gauge (shoulder, hip, small joints)] needle was advanced into the [joint space / suprapatellar pouch / glenohumeral joint] using [palpation landmarks / ultrasound guidance with real-time visualization of needle tip]. [Aspiration confirmed by return of synovial fluid.] [X] mL of [clear / turbid / bloody / purulent] fluid was aspirated. [Corticosteroid / [X] mg triamcinolone with [X] mL 0.5% bupivacaine was injected after aspiration — ONLY after infection was excluded by fluid appearance and clinical assessment. Corticosteroid injection is contraindicated if septic arthritis is suspected until fluid analysis confirms sterile joint.]
Needle removed. Gentle pressure applied. A bandage was placed. Patient tolerated the procedure well without complications. [Fluid sent to laboratory for cell count, differential, crystal analysis, gram stain, and culture.]
None
Synovial fluid sent for cell count, differential, crystal analysis, gram stain, and culture
Minimal
None
Patient discharged home / remaining admitted for further management.
Epic SmartPhrase Version
PREOPERATIVE DIAGNOSIS: [Right / left] [knee / shoulder / hip / ankle] effusion, [septic arthritis / crystal arthropathy / inflammatory / traumatic / unknown]
POSTOPERATIVE DIAGNOSIS: Same
PROCEDURE PERFORMED: Arthrocentesis, [right / left] [knee / shoulder / hip / ankle] [with / without] ultrasound guidance
ATTENDING SURGEON: ***, MD/DO
ANESTHESIA: Local: 1% lidocaine to skin and subcutaneous tissue
INDICATIONS: The patient is a .PTAGE-year-old .PTSEX presenting with [painful / swollen / warm] [right / left] [knee / shoulder] with clinical effusion. [Fever / leukocytosis / elevated CRP] present. Concern for [septic arthritis / gout / pseudogout / inflammatory flare]. Arthrocentesis indicated for diagnosis and therapeutic relief. Risks discussed. Informed consent obtained.
FINDINGS: [Clear / cloudy / turbid / bloody / purulent] synovial fluid aspirated. *** mL removed. Fluid sent for cell count, differential, crystal analysis, gram stain, and culture. [Corticosteroid injected after aspiration.]
DESCRIPTION OF PROCEDURE:
Patient [supine / seated]; [right / left] [knee / shoulder] positioned [in mild flexion / in abduction]. Site identified by [palpation / ultrasound guidance]. Skin prepped with [betadine / chlorhexidine]. 1% lidocaine infiltrated to skin. [18 / 20]-gauge needle advanced into [joint space / suprapatellar pouch / glenohumeral joint] via [medial / lateral / anterior approach] under [palpation / real-time ultrasound guidance with needle tip visualization]. *** mL [clear / turbid / bloody] fluid aspirated. [*** mg triamcinolone with *** mL 0.5% bupivacaine injected after aspiration.] Needle removed; pressure applied; bandage placed. Fluid sent to laboratory. Patient tolerated the procedure well.
ESTIMATED BLOOD LOSS: Minimal
SPECIMENS: Synovial fluid for cell count, differential, crystal analysis, gram stain, and culture
COMPLICATIONS: None
DRAINS: None
DISPOSITION: [Discharged home / Admitted for further management pending culture results]
Signed: .ME, .MYDEGREE
.TODAYVariants
Septic arthritis aspiration (bedside vs. OR)
If septic arthritis is confirmed (WBC >50,000, PMN >75%, positive gram stain), formal OR washout and irrigation is generally indicated rather than serial aspirations. Document urgency of disposition after results return.
Hip arthrocentesis
Hip joint is deep. Ultrasound or fluoroscopic guidance is strongly preferred. Anterior or lateral approach. Document approach, guidance modality, and depth of needle insertion.
Shoulder (glenohumeral) arthrocentesis
Posterior approach (posterior portal landmark) or anterior approach. Ultrasound-guided reduces risk of rotator cuff needle passage. Document approach and landmarks.
Charting Tips
- Document joint aspirated, laterality, and approach (medial, lateral, anterior, posterior)
- State volume and appearance of synovial fluid aspirated
- List all studies sent on the fluid (cell count, crystal, culture at minimum)
- {'Document whether corticosteroid or hyaluronic acid was injected and the drug/dose. Explicitly state that infection was excluded before injection. Do not inject corticosteroid if septic arthritis is suspected. Also document relative contraindications considered': 'recent prior injection (<3 months same joint), overlying cellulitis, bacteremia, uncontrolled diabetes.'}
- Note ultrasound guidance if used, as it is required for separate billing of 76942
- WBC >50,000/mm3 is highly suggestive of septic arthritis but sensitivity is only ~60-70% (Margaretten JAMA 2007). Lower counts do not exclude infection, particularly in gonococcal arthritis, early infection, or prosthetic joints (where threshold is much lower, approximately 1,100-3,000 cells/uL). Clinical suspicion (fever, inability to bear weight, rapid onset monoarthritis) should drive management regardless of cell count.
Billing Tips
- Bill 20610 for arthrocentesis of a major joint (knee, shoulder, hip, sacroiliac joint) WITHOUT ultrasound guidance (0.77 wRVU, 0-day global). Bill 20611 for the same major joints WITH ultrasound guidance (1.07 wRVU, 0-day global) — 20611 includes ultrasound; do not add 76942 separately when billing 20611. Bill 20605 for intermediate joint without US (wrist, elbow, TMJ, 0.66 wRVU); 20606 for intermediate joint with US (0.98 wRVU). Bill 20600 for small joint without US (finger, toe, 0.64 wRVU); 20604 with US. Joint size and whether real-time US guidance with permanent recording was used determines the code.
- Ultrasound guidance: Use 20611 (not 20610 + 76942) when US guidance is used for major joint arthrocentesis. Since 2015, ultrasound guidance has been bundled into the procedure codes 20604/20606/20611 — 76942 is no longer separately billable with these codes. 76942 is only applicable for guidance during aspiration when performed by a separately billing radiologist or provider generating a formal ultrasound report.
- Injection of corticosteroid or hyaluronic acid at the same session: 20610 covers both aspiration and injection. Do not separately bill for the injection procedure. The drug itself (J-code) is separately billable as a supply.
- 0-day global period: follow-up visits after arthrocentesis are fully separately billable with standard E/M codes. There is no bundled postoperative period.
- If performed in the office, modifier -25 may be required on the associated E/M visit to confirm a separately identifiable evaluation and management service was provided on the same day as the procedure. Confirm payer policy.
General coding reference. Verify with your institution’s billing department before submitting claims.